SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-20-055394
Filing Date
2020-10-20
Accepted
2020-10-20 18:14:24
Documents
2
Period of Report
2020-10-19

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1594
2 POA DOCUMENT poa.txt EX-24.3_942038 3551
  Complete submission text file 0001209191-20-055394.txt   6743
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Issuer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O NEOLEUKIN THERAPEUTICS, INC. 360-1616 EASTLAKE AVENUE E. SEATTLE WA 98102
Business Address
Vance Holly (Reporting) CIK: 0001827307 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36327 | Film No.: 201249129